search
obesity
Trends
- 1India moves to ban junk food sales near schools●India tightens school junk food rules amid obesity rise India proposes banning junk food sales in school canteens and wi
India has proposed banning junk food sales in school canteens and within 50 meters of schools, in an effort to curb rising obesity and diabetes rates among children. The rules would restrict children's access to unhealthy food during and around the school day. The proposal comes as health officials warn that poor diets are driving growing rates of childhood obesity and related diseases across the country.
- 2Shocking Side Effects of Obesity Drugs Revealed●Shocking Side Effects of Obesity Drugs Finally Revealed (A Medicine Turned Poison...?) | Science ...
A science-focused explorer claims obesity medications may carry serious, previously underreported side effects, framing the situation as a medicine turned poison. The piece suggests people using or considering weight-loss drugs should pay closer attention to adverse reactions. No specific drug names, findings, or medical sources are given, so the scale of the alleged risks remains unclear, but the topic is drawing large attention amid the global boom in weight-loss injections.
- 3Oral GLP-1 drug safiglipron shows promise in early type 2 diabetes trial●Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
A randomized, double-blind, placebo-controlled trial published in Nature reports that safigliptron, an oral small-molecule GLP-1 receptor agonist, was tested in people with early type 2 diabetes. The publication is drawing attention as GLP-1 drugs reshape diabetes and obesity treatment, and an oral small-molecule option could be easier to take than injectable alternatives. Details on efficacy and safety are being reviewed by clinicians and researchers.
- 4GLP-1 Drugs Reshape the Weight Loss and Mental Health Story●GLP-1s Are Rewriting the Story of Weight Loss and Mental Health
Drugs in the GLP-1 class, such as Ozempic and Wegovy, are being credited not just with helping people lose weight but with improving mood and mental wellbeing, challenging long-held assumptions about obesity and appetite. The Atlantic reports that researchers are increasingly studying how these medications affect the brain, food cravings, and emotional health, with patients describing reduced urges to eat and sometimes notable shifts in their overall mental state.